1 / 11

Breast Cancer Tumor Board

Chair Harold Burstein, MD, PhD Faculty Jennifer Bellon, MD Mehra Golshan, MD. Breast Cancer Tumor Board. Patient Presentation. 55-year-old woman who works as a medical office administrator Screening mammogram showed abnormality in breast

iram
Télécharger la présentation

Breast Cancer Tumor Board

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chair Harold Burstein, MD, PhD Faculty Jennifer Bellon, MD Mehra Golshan, MD Breast Cancer Tumor Board

  2. Patient Presentation • 55-year-old woman who works as a medical office administrator • Screening mammogram showed abnormality in breast • Core biopsy revealed invasive cancer with associated ductal carcinoma in situ • Invasive component considered intermediate grade • She underwent lumpectomy and sentinel lymph node mapping • Lumpectomy revealed a 1.7 cm, grade 2 (moderately differentiated) invasive ductal carcinoma

  3. Further Tumor Testing • Sentinel lymph node mapping • 2 lymph nodes identified • 1 node contained a 2-mm focus of invasive cancer seen on hematoxylin and eosin stain • Tumor immunophenotyping • Estrogen receptor positive • Progesterone receptor low positive • HER2 1+ • HER2 status determination by fluorescence in situ hybridization (FISH) • No evidence for gene amplification, with a ratio of 1.2

  4. Patient History and Exam • Patient is otherwise well • Borderline high cholesterol • Postmenopausal, grava 3 para 2 with a miscarriage • No medications • Medical allergy to sulfa products (rash) • No family history of breast cancer • Comprehensive system review notable only for her postoperative treatment changes

  5. Mammogram—Magnification View Graphic courtesy of Dr. Mehra Golshan.

  6. Ultrasound View of Lesion Graphic courtesy of Dr. Mehra Golshan.

  7. Specimen Imaging Showing Wire and Calcifications Graphic courtesy of Dr. Mehra Golshan.

  8. ALND (n = 420) SLND (n = 436) ACOSOG Z0011—5-Year Recurrence Rates Recurrence P = .11, ALND vs SLND. Abbreviations: ALND, axillary lymph node dissection; SLND, sentinel lymph node dissection.Giuliano AE, et al. J Clin Oncol. 2010;28:18S.

  9. ACOSOG Z0011—Predictors of Locoregional Recurrence in Multivariate Analysis Giuliano AE, et al. J Clin Oncol. 2010;28:18S

  10. ACOSOG Z0011: Predictors of Disease-Free Survival in Multivariate Analysis Giuliano AE, et al. J Clin Oncol. 2010;28:18S

  11. Conclusions • ACOSOG Z0011 was a study of completion dissection or not for women with positive sentinel lymph nodes • There was no apparent benefit for completion dissection as both groups had very low risk of local and regional breast cancer recurrence • The trial closed having accrued only half its patients and remains somewhat underpowered • Moving forward, it is likely that surgical treatment decisions will be individualized • Role of axillary dissection to be based on tumor size, extent of nodal disease, biological features of the breast cancer, patient age, and other traditional risk factors

More Related